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http://dx.doi.org/10.1016/j.jfma.201Purpose: To evaluate the treatment outcomes and toxicity in endometrial cancer patients
treated with hysterectomy and adjuvant intensity-modulated radiation therapy (IMRT) or con-
ventional radiotherapy (CRT).
Methods: There were 101 patients with stage IA-IIIC2 endometrial carcinoma treated with hys-
terectomy and adjuvant radiotherapy. In total, 36 patients received adjuvant CRT and 65 were
treated with adjuvant IMRT. The endpoints were overall survival, local failure-free survival,
and disease-free survival. Patients were assessed for acute toxicity weekly according to the
Common Terminology Criteria for Adverse Events version 3.0. Late toxicity was evaluated ac-
cording to the Radiation Therapy Oncology Group and the European Organization for Research
and Treatment of Cancer Late Radiation Morbidity Scoring Schema.
Results: The 5-year overall survival, local failure-free survival, and disease-free survival for
the CRT group and the IMRT group were 82.9% versus 93.5% (p Z 0.26), 93.7% versus 89.3%
(p Z 0.68), and 88.0% versus 82.8% (p Z 0.83), respectively. Four (11.1%) patients had Grade
3 or greater acute gastrointestinal (GI) toxicity and three (8.3%) patients had Grade 3 or
greater acute genitourinary (GU) toxicity in the CRT group, whereas four (6.2%) patients had
Grade 3 or greater acute GI toxicity in the IMRT group and no patient had severe GU toxicity.
There was one (2.8%) patient who had Grade 3 or greater late GI toxicity and one (2.8%) patient
had Grade 3 or greater late GU toxicity in the CRT group, whereas no patient had severe GI or
GU toxicity in the IMRT group.of Radiation Oncology, Taichung Veterans General Hospital, Number 160, Chung-Kang Road, Section
.com (L. Wang).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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950 C.-C. Chen et al.Conclusion: Adjuvant IMRT for endometrial cancer patients had comparable clinical outcomes
with CRT and had less acute and late toxicity.
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Endometrial cancer is one of the most common gynecologic
cancers. The mainstay treatment for endometrial cancer is
total abdominal hysterectomy and bilateral salpingo-
oophorectomy. The Postoperative Radiation Therapy in
Endometrial Carcinoma (PORTEC)-1 study1 found that
adjuvant whole pelvis radiotherapy (WPRT) had the great-
est loco-regional benefit in endometrial cancer patients
who had two or more risk factors, including age 60 years,
Grade 3 disease, and 50% myometrial invasion. The Gy-
necologic Oncology Group (GOG)-99 study2 defined high
intermediate risk patients as: (1) moderate to poorly
differentiated tumor, presence of lymphovascular invasion,
and outer third myometrial invasion; (2) age 50 years or
greater with any two risk factors listed above; or (3) age of
at least 70 years with any risk factor listed above, and they
showed that adjuvant WPRT improved loco-regional control
for high intermediate risk patients. Aalders et al3 found
that poor prognostic factors were International Federation
of Obstetrics and Gynecology (FIGO) Stage Ic disease, Grade
3 disease, lymph-vascular invasion, and age >60 years and
showed that adjuvant WPRT decreased pelvis and vaginal
recurrence. WPRT is commonly used in postoperative
treatment in endometrial cancer in previous randomized
trials. Conventional WPRT determines the field by bony
landmark alone and is capable of including most of the
normal organs of the pelvis in the area of the prescribed
dose. After surgery, a significant portion of the small bowel
falls into the vacated space in the pelvis, thereby
increasing the volume of bowel that receives a high dose. A
large portion of the urinary bladder is also included in the
field of radiotherapy. This increases the risk of acute and
late gastrointestinal (GI) and genitourinary (GU) toxicity.
Several studies4e8 showed that intensity-modulated radio-
therapy (IMRT) reduces the irradiated volume of normal
tissue in gynecologic malignancies and this tends to lessen
the acute and late GI and GU toxicity. To the best of our
knowledge, only two studies9,10 have compared WPRT and
IMRT and the results showed a potential dosimetric advan-
tage of IMRT over WPRT in postoperative endometrial can-
cer patients. To date, few studies11e13 have evaluated the
clinical outcomes of IMRT in endometrial cancer.
The purpose of this study was to evaluate and compare
treatment outcomes and toxicity of IMRT and conventional
radiotherapy (CRT).
Methods and materials
Patients
From January 2000 to October 2010, there were 101 eligible
patients with endometrial cancer documented at the radi-
ation oncology department of Taichung Veterans GeneralHospital, Taiwan. The inclusion criteria were: (1) patho-
logically proven adenocarcinoma or endometrioid carci-
noma of endometrium; (2) no evidence of distant
metastasis at diagnosis; (3) patients receiving complete
surgical staging with hysterectomy, bilateral pelvic lymph
nodes dissection, and bilateral salpingo-oophorectomy; and
(4) patients receiving a full course of adjuvant radio-
therapy. The exclusion criteria were: (1) pathology with
serous carcinoma, mucinous carcinoma, clear cell carci-
noma and sarcoma; and (2) no surgical staging.
In this institution, adjuvant radiotherapy was indicated
for endometrial cancer patients with one or more risk
features, including: (1) age 60 years; (2) FIGO Stage Ib or
more advanced stage; (3) Grade 2e3; (4) 50% myometrial
invasion; (5) cervical involvement; (6) lymphevascular in-
vasion; (7) pelvic and/or para-aortic lymph nodes metas-
tasis; (8) close (<5 mm) or involved resection margin; and
(9) incomplete pelvic lymph nodes dissection, to improve
the locoregional control rate. Complete lymph node
dissection was defined as common, internal, external, and
obturator lymph node dissection and sampling para-aortic
lymph nodes.
Thirty-six patients received adjuvant CRT between
January 2000 and October 2003. Sixty-five patients were
treated with adjuvant IMRT from October 2003 to October
2010. Twenty-eight patients received a high dose rate
brachytherapy of 8e24 Gy to the vagina vault as a local
boost, which included four patients in the CRT group and 24
patients in the IMRT group. Brachytherapy was given based
on the physician’s decision according to the patient’s in-
dividual clinical situation, such as involvement of lower
uterine segment or cervix and/or vaginal invasion.
The pathological staging was performed according to the
2010, 7th edition FIGO staging system. Written informed
consent was obtained from each patient before treatment.
The study was approved by the Institutional Review Board
of Taichung Veterans General Hospital (CE11304).RT technique
All patients were scheduled to undergo adjuvant radio-
therapy. CRT included two- and three-dimensional radio-
therapy. CRT was delivered either through the
anterioreposterior and posterioreanterior field or with a
four-field treatment plan. The field covered the entire
pelvis, including the upper half of the vagina, paravaginal
area, parametrium, uterosacral tissues, and external iliac,
hypogastric and obturator lymph nodes. The superior
border was defined at the L4e5 interspace, the inferior
border was at the mid-portion of the obturator foramen,
and the lateral borders were set at 1.5e2.0 cm beyond the
lateral margins of the bony pelvic wall at the widest plane
of the pelvis. The posterior border of lateral field was the
anterior border of the S3 vertebral body and the anterior
Figure 1 This 43-year-old female had International Federation of Obstetrics and Gynecology Stage Ib endometrial cancer and
received hysterectomy, bilateral pelvic lymph nodes dissection, bilateral salpingo-oophorectomy, and para-aortic lymph nodes
dissection. A total dose of 50.4 Gy was planned by Eclipse software. The isodose curve was compared for intensity modulated
radiotherapy (IMRT) and cradiotherapy (CRT). This figure shows the different dose distributions of CRT (right) and IMRT (left). In
axis view and sagittal view, the bowel and the bladder received a significantly lower dose in the IMRT plan than in the CRT plan.
Outcomes of endometrial cancer treatment 951border of the symphysis pubis. No pelvic structures were
blocked during the radiotherapy treatment course. The
dose of CRT was usually 50.4 Gy in 28 fractions, 1.8 Gy/
fraction, and five fractions/week. Patients received CRT in
the supine position and immobilized by a custom vacuum
lock bag.
The IMRT planning and all treatments were performed in
the supine position with a full bladder. This was achieved by
asking patients to empty their bladder 30 minutes before
computed tomography (CT) simulation and daily treatment
and drink 300 mL of water. A custom vacuum lock bag was
used for pelvic immobilization for CT simulation and daily
treatment. IMRT treatment was delivered using a dynamic
multileaf linear accelerator with photon energy of 10 MV.
Eclipse software was used for treatment planning of
intensity-modulated radiotherapy. The gross target volume
(GTV) was defined as parametrium, upper vagina, and
paravaginal tissues. The clinical target volume (CTV) was
delineated including a 0.5e1.0 cm margin to GTV radially
and the pelvic lymph node regions (common, internal,
external iliacs, and obturator lymph nodes), for all the
patients. For patients with cervical stromal invasion, the
presacral lymph node region was also contoured to the
inferior border of S2. A margin of 0.5e1 cm was added to
the “vessels” contour in all dimensions and modified by
anatomic boundaries to create the nodal clinical targetvolume, from which the pelvic bones, femoral heads, and
vertebral bodies were excluded. Planned target volume
(PTV) with a 0.7e1 cm margin superiorly, inferiorly, and
radially was given to the CTV. A total dose of 50.4e60 Gy in
28e30 fractions, 1.8e2.0 Gy/fraction, and five fractions/
week, was delivered to the GTV, and the isodose curve of
50.4e60 Gy encompassed 100% of the GTV. A total dose of
45e48 Gy in 28e30 fractions was given to the PTV, and the
isodose curve of 45e48 Gy encompassed 100% of the CTV
and >99% of the PTV.
If patients had para-aortic lymph node metastasis,
extended field radiotherapy with IMRT technique was
given. CTV encompassed the para-aortic lymph nodes area
and pelvic lymph nodes region with the superior border
extending to the T12eL1 interspace. CTV was expanded by
0.7e1 cm to create the PTV and a total dose of 45e48 Gy in
28e30 fractions was given to PTV.
The critical organs contoured included the bladder,
rectum, small intestine, and colon on every slice. The
rectum is usually defined from the level of anus to the
sigmoid flexure and received a dose of V30 <50%. The small
bowel loops and colon were outlined with the treatment
field plus a 2 cm margin and a dose of V30 <15% was given.
The received dose of bladder was restricted to V45 <35%.
Fig. 1 shows the different dose distributions of CRT and
IMRT.
Table 1 Patient’s characteristics.
CRT
(n Z 36)
IMRT
(n Z 65)
Age (y) Median 59 54
Range 32e81 27e79
Age 60 y 17 (47.2) 17 (26.2)
FIGO Stage Ia 6 (16.7) 14 (21.5)
Ib 11 (30.5) 24 (37.0)
II 9 (25.0) 9 (13.8)
IIIa 5 (13.9) 6 (9.2)
IIIb 0 0
IIIc 5 (13.9) 12 (18.5)
IV 0 0
LVSI 4 (11.1) 19 (29.2)
Grade 1 3 (8.3) 11 (16.9)
2 20 (55.6) 33 (50.8)
3 13 (36.1) 21 (32.3)
Incomplete LN dissection 2 (5.6) 5 (7.7)
Margina 3 (8.3) 10 (15.4)
RT field Pelvis 32 (88.9) 57 (87.7)
Extended 4 (11.1) 8 (12.3)
RT dose, Gy 50.4 45e60
Chemotherapy 2 (5.6) 9 (13.8)
Brachytherapy 4 (11.1) 24 (36.9)
Data are presented as n (%), unless otherwise indicated.
CRT Z conventional radiotherapy; FIGO Z International
Federation of Obstetrics and Gynecology; IMRT Z intensity-
modulated radiotherapy; LVSIZ lymph vascular space invasion;
LN Z lymph nodes.
a Margin included close margin (<5 mm) and involved margin.
Figure 3 Local failure-free survival.
Table 2 Acute toxicity.
CRT (n Z 36) IMRT (n Z 65)
Skin Grade 1 1 (2.8) 3 (4.6)
2 0 5 (7.7)
3 0 0
952 C.-C. Chen et al.The source used in high-dose rate brachytherapy was
iridium-192. A cumulative dose of 8e24 Gy was prescribed
at a depth of 0.5 cm from vaginal surface in 2e6 fractions,
two fractions/week. Four patients received brachytherapy
after CRT, ranging from 10e16 Gy. Brachytherapy, ranging
from 8e24 Gy, was delivered in 24 patients after IMRT.
Sequential chemotherapy with a cisplatin, doxorubicin,
and taxel-based regimenwas considered inpatientswith FIGO
Stage III disease before and/or after adjuvant radiotherapy.
Chemotherapy was delivered according to the patients’ clin-
ical condition. Chemotherapy was given in 11 patients, which
included two in the CRT group and nine in the IMRT group.Figure 2 Overall survival.Statistical analysis
The endpoints were overall survival (OS), local failure-free
survival (LFFS), and disease-free survival (DFS). OS was
defined as the time from the date of operation to the date
of death from any cause or last follow-up. LFFS was
measured from the date of operation to the date of any
evidence of local recurrence or last follow-up. The DFS was
calculated from the date of operation to the date of any
evidence of local recurrence, or distant metastasis or last
follow-up. Survival times were estimated using the
KaplaneMeier method. Univariate comparison of survival
curves were performed using the log-rank test. The statis-
tical analyses were performed using SPSS software, version
10.0 (SPSS Inc., Chicago, IL, USA). A p value of <0.05 was
regarded as statistically significant.
Acute GI and hematological toxicity were assessed
weekly using the Common Terminology Criteria for Adverse4 0 0
GI Grade 1 5 (13.9) 25 (38.5)
2 20 (55.6) 18 (27.7)
3 4 (11.1) 2 (3.1)
4 0 2 (3.1)
GU Grade 1 2 (5.6) 10 (15.4)
2 7 (19.4) 11 (16.9)
3 3 (8.3) 0
4 0 0
Hematological 1 2 (5.6) 8 (12.3)
2 1 (2.8) 3 (4.6)
3 0 2 (3.1)
4 0 0
Data are presented as n (%).
CRT Z conventional radiotherapy; GI Z gastrointestinal;
GUZ genitourinary; IMRTZ intensity-modulated radiotherapy.
Table 3 Late toxicity.
CRT (n Z 36) IMRT (n Z 65)
Skin GI GU Skin GI GU
Grade 1 2 (5.6) 3 (8.3) 1 (2.8) 2 (3.1) 0 4 (6.2)
2 0 7 (19.4) 1 (2.8) 1 (1.5) 2 (3.1) 4 (6.2)
3 0 1 (2.8) 1 (2.8) 0 0 0
4 0 0 0 0 0 0
Data are presented as n (%).
CRT Z conventional radiotherapy; GI Z gastrointestinal;
GUZ genitourinary; IMRTZ intensity-modulated radiotherapy.
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physical examinations or imaging studies were performed
every 3 months for the first 2 years, and every 6 months
during Years 3e5, according to Radiation Therapy Oncology
Group criteria.
Results
Table 1 summarizes the patients’ characteristics. The me-
dian age of the CRT groupwas 59 years, ranging from32 years
to 81 years; and that of the IMRT group was 54 years, ranging
from 27 years to 79 years. In the CRT group, 17 patients had
FIGO Stage I disease, nine patients had Stage II disease, and
10 patients had FIGO Stage III. In the IMRT group, 38 patients
had FIGO Stage I disease, nine patients had Stage II disease,
and 18 patients had Stage III disease. Of 36 patients receiving
CRT, 32 patients received pelvis radiation field and four pa-
tients received extended field radiotherapy. In 65 patients
receiving IMRT, pelvis radiation fields were delivered in 57 of
them and eight patients received extended field radio-
therapy. Brachytherapy was given after CRT in four patients
and after IMRT in 24 patients.
The median follow-up time was 101 months for the CRT
group patients, ranging from 2months to 134 months; and 61
months for the IMRTgroup patients, ranging from3months to
106 months. The 5-year OS, LFFS, and DFS for all patients
were 89.5%, 91.0%, and 84.9%, respectively. The 5-year OS,Table 4 Summary of studies on toxicity of adjuvant radiothera
Study Acute Grade
3 or 4 GI toxicity
Acute Grade
3 or 4 GU toxicity
Tierney et al12 0 0
Beriwal et al13 0 0
Bouchard et al11 6.6 0
Creutzberg et al1 NA NA
Keys et al2 7.9 0
Sutton et al14 15 0
Martinez et al15 NA NA
Current study
CRT 11.1 8.3
IMRT 6.2 0
Data are presented as %.
CRT Z conventional radiotherapy; GI Z gastrointestinal; GU Z gen
available.LFFS, and DFS for the CRT group and the IMRT group were
82.9% vs. 93.5% (pZ 0.26, Fig. 2), 93.7% vs. 89.3% (pZ 0.68,
Fig. 3), and 88.0% vs. 82.8% (pZ 0.83), respectively.
In the CRT group, six (16.7%) patients had tumor relapse
and five (13.9%) patients died of disease. Three (8.3%) pa-
tients experienced local and/or regional failure. One pa-
tient had vaginal recurrence; one patient had lymph node
recurrence; and one patient had both vaginal and lymph
node recurrence. Of these three patients, local radio-
therapy was chosen as salvage treatment. Three (8.3%)
patients had distant metastasis in CRT group. Two patients
had lung metastasis and one experienced spleen metas-
tasis. All these three patients received chemotherapy.
In the IMRT group, 10 (15.4%) patients experienced
tumor relapse and six (9.2%) patients died of disease. Four
patients had locoregional recurrence; four patients expe-
rienced distant metastasis; and two patients had both
locoregional and distant metastasis. Of these six (9.2%)
patients had local and/or regional failure, three patients
had peritoneal carcinomatosis; two patients had vaginal
recurrence; and one patient had lymph node recurrence.
Two patients received local radiotherapy as a salvage
treatment and the other four patients used chemotherapy.
Of six (9.2%) patients with distant metastasis, three had
lung metastasis, two had brain metastasis, and one expe-
rienced liver metastasis. Operation and/or radiotherapy
were chosen as a salvage treatment for brain metastasis
lesions. Patients with lung or liver metastasis received
salvage chemotherapy.
Acute toxicity is summarized in Table 2. There were four
(11.1%) patients who had Grade 3 acute GI toxicity and
three (8.3%) patients had Grade 3 acute GU toxicity in the
CRT group. In six patients who experienced Grade 3 acute
toxicity and one of them had both Grade 3 GI and GU
toxicity, four had FIGO Stage III disease and received
extended field radiotherapy and two had Stage II disease.
Four patients (6.2%) had Grade 3 or 4 acute GI toxicity in
the IMRT group; two patients had Stage II disease and the
other two patients had Stage I disease. No patient had
Grade 3 or 4 acute GU toxicity in the IMRT group.
Late toxicity is summarized in Table 3. In the CRT group,
one (2.8%) patient had Grade 3 late GI toxicity and receivedpy.
Late Grade
3 or 4 GI toxicity
Late Grade
3 or 4 GU toxicity
Technique
NA NA IMRT
2.1 0 IMRT
0 0 IMRT
2 NA Conventional RT
NA NA Conventional RT
NA NA Conventional RT
14 3.5 Conventional RT
2.8 2.8 Conventional RT
0 0 IMRT
itourinary; IMRT Z intensity-modulated radiotherapy; NA Z not
954 C.-C. Chen et al.long-term treatment with medication, and one (2.8%) pa-
tient had Grade 3 late GU toxicity for which surgical inter-
vention was performed to relieve the symptom. No patient
had Grade 3 or 4 late GI and GU toxicity in the IMRT group.Discussion
Creutzberg et al1 found that the LFFS was 95.8% for FIGO
Stage I endometrial cancer patients who received post-
operative conventional pelvic radiotherapy. In studies by
Keys et al2 on Stage IeII and by Aalders et al3 on Stage I,
endometrial cancer patients were treated with CRT and the
locoregional control rate was over 90%. Bouchard et al11
compared IMRT and CRT and showed that the 3-year dis-
ease control rates for IMRT and CRT were 100% and 82%,
respectively. In our study, we analyzed 101 patients with
Stage IeIII endometrial cancer and showed that the 5-year
locoregional control rate (91%) was excellent. The FIGO
stage and adjuvant brachytherapy are thought to be factors
that affect local and regional control, but there was no
significant difference in LFFS between the IMRT group and
the CRT group (p Z 0.62).
Table 41,2,11e15 summarizes acute and late GI and GU
toxicity of our and previous studies. Keys et al2 also treated
patients with adjuvant CRT and found that 3.2% (6 of 190) of
patients had Grade 3 or 4 GI obstruction and 4.7% (9 of 190)
of patients had other Grade 3 or greater GI complications.
They also reported that there was no Grade 3 or 4 late GU
toxicity. Tierney et al12 reported the acute toxicity of
postoperative IMRT for endometrial cancer and showed that
13 of 19 patients (68%) experienced Grade 1 or 2 acute GI
toxicity and 5 of 19 patients (26%) had Grade 1 or 2 acute
GU toxicity, but none of them developed Grade 3 or 4 acute
GI and GU toxicity during irradiation. Beriwal et al13
analyzed 47 endometrial cancer patients treated with
IMRT and found that 46 patients (97.9%) had Grade 1 or 2
acute GI toxicity and nine patients (19.1%) had Grade 1 or 2
acute GU toxicity, whereas no patients experienced Grade
3 or 4 acute GI and GU toxicity. In this study, 29 of 36 pa-
tients (80.6%) had acute GI toxicity and four (11.1%) of
them had Grade 3 acute GI toxicity in the CRT group; 47 of
65 patients (72.3%) had acute GI toxicity and 4 (6.2%) of
them experienced Grade 3 or 4 acute GI toxicity in the IMRT
group. Of the four patients of the IMRT group with severe
acute GI toxicity, two patients received pelvic radiotherapy
50.4 Gy plus brachytherapy 8 Gy; one patient received
50.4 Gy external beam radiotherapy alone; and one patient
received 55.8 Gy external beam radiotherapy alone. There
were no significant difference of the dose-volume histo-
gram between these four patients and the other patients
who did not have severe GI toxicity. Of these four patients,
two had wound infection and poor wound healing, one had
abdominal pain and intractable watery diarrhea after
radical surgery, and the other patient had severe abdominal
pain after surgery. They had GI symptoms, including diar-
rhea and abdominal pain, and local wound problems prior
to when adjuvant radiotherapy was given. Thirteen pa-
tients (36.1%) developed acute GU toxicity and three (8.3%)
of them had Grade 3 acute GU toxicity in the CRT group; 21
(32.3%) patients had acute GU toxicity and none of them
had Grade 3 or 4 GU toxicity in the IMRT group. According tothe results of previous studies12,13 and the findings of the
present study, the most common acute side effects were GI
and GU toxicity, and IMRT had the potential to reduce
Grade 3 or 4 acute GI and GU toxicity.
Creutzberg et al1 treated patients with postoperative
CRT and reported that 25% of patients had late complica-
tions. The most common complications were GI toxicity and
they also found that only 2.0% (7 of 354) had Grade 3 or
greater complications. Bouchard et al11 treated patients
with adjuvant IMRT and showed that there were no Grade 3
or 4 late GI or GU toxicity. Beriwal et al13 also treated pa-
tients with postoperative IMRT and reported that 2.1% (1 of
47) of patients experienced Grade 3 late GI toxicity and
none of them had Grade 3 or 4 late GU toxicity. In our study,
most common late toxicity in the CRT group was GI
complication. There were 11 patients (30.6%) who had late
GI toxicity and one (2.8%) of them experienced Grade 3
toxicity. In the IMRT group, there was less late GI toxicity.
Only two patients (3.1%) had late GI complication and no
patients experienced Grade 3 or greater GI toxicity. We also
found that late GU complications were comparable in the
CRT group and the IMRT group. In the CRT group, three
patients (8.3%) had GU complications and one (2.8%) of
them experienced Grade 3 GU complication. Eight patients
(12.3%) had late GU complication in the IMRT group, but
none of them had Grade 3 or greater GU toxicity. There was
no significant reduction of GU toxicity in the IMRT group,
but the incidence of Grade 3 or 4 late GU toxicity was less in
the IMRT group.
In the IMRT group, eight patients had Stage III disease
and received extended field radiotherapy. Five of them had
acute Grade 2 GI toxicity and two patients experienced
Grade 1 GI toxicity; two patients had Grade 1 GU toxicity
and Grade 2 GU toxicity occurred in one patient. None of
them had Grade 3 or 4 acute GI and GU toxicity. In CRT
group, four patients with Stage III received extended field
radiotherapy and one of them had Grade 3 GI toxicity. The
IMRT technique has the potential benefit to lower the dose
of intestine and decrease GI toxicity, especially when the
radiotherapy field is extended.
There were more patients receiving chemotherapy (5.6%
vs. 13.8%) and brachytherapy (11.1% vs. 36.9%) in the IMRT
group in the retrospective study. The treatment protocol
varied according to the physicians’ preference and the
different time. There were more FIGO Stage IIIc patients
(13.9% vs. 18.5%), more lymph vascular space invasion
(11.1% vs. 29.2%), and more close margin status (8.3% vs.
15.4%) in the IMRT group. These three factors could also
affect the LFFS and DFS. These could be the reasons for
IMRT having slightly lower LFFS and DFS.
There were some limitations in this study and these
include the use of a retrospective study design and the
small sample size. The small number of patients limited our
ability to perform multiple adjustments for potential con-
founders and the power of our analysis to detect small
differences. In addition, the combination of chemotherapy
and adjuvant brachytherapy for postoperative endometrial
cancer could have affected the clinical outcomes and
toxicity. A large, prospective, and randomized trial is
needed to evaluate and compare the toxicity and clinical
outcomes of endometrial cancer patients treated with
adjuvant IMRT or CRT.
Outcomes of endometrial cancer treatment 955In conclusion, adjuvant IMRT for endometrial cancer
patients had comparable clinical outcomes with CRT and
had less acute and late toxicity. IMRT is a better choice for
adjuvant treatment of endometrial cancer patients to avoid
severe acute and late radiation complications.
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